376 selected records with a cited source date in 2025, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.
PubMed lists PMID 41458027 in Frontiers in psychiatry as Journal Article, Review, with publication-date metadata of 2025-12-11 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41341140 in Frontiers in endocrinology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 30 for the reviewed Tirzepatide label family with a published date of 2025-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03596905 at 2026-07-30T18:18:33.534Z. Its registry update date was 2025-12-31, and PeptideScanner's reviewed identity mapping was plecanatide.
PubMed lists PMID 11321250 in Folia biologica as Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide.
DailyMed lists Structured Product Labeling version 9 for the reviewed Leuprolide label family with a published date of 2025-12-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06921824 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT07300982 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT07128082 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-23, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05568160 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was vasopressin.
DailyMed lists Structured Product Labeling version 59 for the reviewed Dulaglutide label family with a published date of 2025-12-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 13 for the reviewed Setmelanotide label family with a published date of 2025-12-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 218316 with status AP dated 2025-12-22, and names semaglutide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT07262957 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was octreotide.
PubMed lists PMID 41403449 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug efpeglenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.
The Federal Register published notice 2025-23409, attributed to FDA and its parent HHS department, on 2025-12-19. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide),” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT00117286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT07265752 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07292519 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide.
PubMed lists PMID 41133754 in Journal of investigational allergology & clinical immunology as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41270816 in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases as Journal Article, Review, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT07176663 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 41373628 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-11-27 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41368449 in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine as Journal Article, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213641 with status AP dated 2025-12-12, and names teriparatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216589 with status AP dated 2025-12-12, and names octreotide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide.
The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 41340868 in Genetics in medicine open as Journal Article, with publication-date metadata of 2025-10-13 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38320524 in NEJM evidence as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06588504 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was glucagon.
DailyMed lists Structured Product Labeling version 13 for the reviewed Semaglutide label family with a published date of 2025-12-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT00001481 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05189457 at 2026-07-30T18:18:33.510Z. Its registry update date was 2025-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06815133 at 2026-11-15T21:46:36.651Z. Its registry update date was 2025-12-03, and PeptideScanner's reviewed identity mapping was zilucoplan.
PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT01225055 at 2026-07-30T18:18:33.512Z. Its registry update date was 2025-12-02, and PeptideScanner's reviewed identity mapping was teriparatide.
PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05148299 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.
DailyMed lists Structured Product Labeling version 16 for the reviewed Vosoritide label family with a published date of 2025-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07104500 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-11-24, and PeptideScanner's reviewed identity mapping was vk2735.
PubMed lists PMID 41029353 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2025-09-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2025-20548, attributed to FDA and its parent HHS department, on 2025-11-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.
PubMed lists PMID 41078071 in Hormone research in paediatrics as Case Reports, Journal Article, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT07242612 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-21, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06052787 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide.
PubMed lists PMID 39394922 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2024-10-12 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 1 for the reviewed Bremelanotide label family with a published date of 2025-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41134515 in Advances in therapy as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 9 for the reviewed Afamelanotide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 36 for the reviewed Linaclotide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 12 for the reviewed Semaglutide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 28 for the reviewed Tirzepatide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 41227129 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-10-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215826 with status AP dated 2025-11-13, and names leuprolide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.
PubMed lists PMID 35923949 in Frontiers in public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-07-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05096403 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-10-30, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT05929339 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-10-28, and PeptideScanner's reviewed identity mapping was oxytocin.
PubMed lists PMID 40692281 in Clinical and experimental dermatology as Journal Article, with publication-date metadata of 2025-10-27 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT04843761 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was aviptadil.
PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PubMed lists PMID 20135020 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-12 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40764045 in BMJ open gastroenterology as Journal Article, with publication-date metadata of 2025-08-05 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03822468 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-10-16, and PeptideScanner's reviewed identity mapping was goserelin.
PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03069937 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-10-15, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT06994338 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-14, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06729606 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-09, and PeptideScanner's reviewed identity mapping was aviptadil.
PeptideScanner retained ClinicalTrials.gov record NCT00262470 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-08, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT06828055 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-10-06, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT06872060 at 2026-07-30T18:20:54.427Z. Its registry update date was 2025-10-03, and PeptideScanner's reviewed identity mapping was glucagon.
The Federal Register published notice 2025-19281, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.
The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 30788534 in Journal of molecular medicine (Berlin, Germany) as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-02-20 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 33468709 in Aging as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-01-19 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 35275476 in Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216294 with status AP dated 2025-09-26, and names calcitonin salmon among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 40985013 in Journal of pain research as Journal Article, with publication-date metadata of 2025-09-17 (day precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2025-18453, attributed to FDA and its parent HHS department, on 2025-09-24. Its official title is “Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06847399 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 40960088 in Archivum immunologiae et therapiae experimentalis as Journal Article, Review, with publication-date metadata of 2025-09-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06901245 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-16, and PeptideScanner's reviewed identity mapping was tirzepatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218813 with status AP dated 2025-09-15, and names glucagon among the application record's active ingredients.
PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40821249 in Cureus as Journal Article, Review, with publication-date metadata of 2025-07-15 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.
PubMed lists PMID 40685269 in Revue neurologique as Letter, with publication-date metadata of 2025-07-19 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39530977 in The American surgeon as Journal Article, with publication-date metadata of 2024-11-12 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40555685 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2025-06-24 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT03000946 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained PubMed bibliographic metadata for PMID 40929642 at 2026-07-30T18:22:54.035Z. PubMed recorded a metadata revision date of 2025-09-10 and an Entrez history date of 2025-09-10. PeptideScanner associated this retained record with the identity slug mazdutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 40929641 at 2026-07-30T18:22:54.035Z. PubMed recorded a metadata revision date of 2025-09-10 and an Entrez history date of 2025-09-10. PeptideScanner associated this retained record with the identity slug mazdutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 12 for the reviewed Setmelanotide label family with a published date of 2025-09-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT06193616 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-05, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT05364931 at 2026-11-16T01:47:38.899Z. Its registry update date was 2025-09-03, and PeptideScanner's reviewed identity mapping was cotadutide.
PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40869425 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-08-21 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.
DailyMed lists Structured Product Labeling version 11 for the reviewed Semaglutide label family with a published date of 2025-08-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03822975 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was bivalirudin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214568 with status AP dated 2025-08-27, and names liraglutide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide.
The Federal Register published notice 2025-16269, attributed to FDA and its parent HHS department, on 2025-08-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 40609154 at 2026-07-30T18:24:19.064Z. PubMed recorded a metadata revision date of 2025-08-26 and an Entrez history date of 2025-07-03. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 40836563 in Journal of clinical research in pediatric endocrinology as Journal Article, with publication-date metadata of 2025-08-21 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide.
DailyMed lists Structured Product Labeling version 1 for the reviewed Glucagon label family with a published date of 2025-08-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT07128394 at 2026-11-15T21:49:16.513Z. Its registry update date was 2025-08-19, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT04321408 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-17, and PeptideScanner's reviewed identity mapping was ziconotide.
DailyMed lists Structured Product Labeling version 13 for the reviewed Exenatide label family with a published date of 2025-08-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 19502544 in Diabetes care as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-06-05 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05984537 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-12, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.
PubMed lists PMID 40771220 in Frontiers in nutrition as Case Reports, Journal Article, with publication-date metadata of 2025-07-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 12 for the reviewed Exenatide label family with a published date of 2025-08-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT05895643 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 20069136 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-10 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2025-14683, attributed to FDA and its parent HHS department, on 2025-08-04. Its official title is “Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
PubMed lists PMID 40731360 in Critical care (London, England) as Journal Article, Review, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 23 for the reviewed Lixisenatide label family with a published date of 2025-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03298087 at 2026-07-30T18:23:09.823Z. Its registry update date was 2025-08-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05821075 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-07-31, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PubMed lists PMID 37815317 in Current opinion in ophthalmology as Review, Journal Article, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38353275 in Current opinion in gastroenterology as Review, Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38350110 in Nano letters as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-13 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT07090343 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 35838488 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-08-03 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 35926348 in Thrombosis research as Journal Article, with publication-date metadata of 2022-07-25 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 34623544 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-10-08 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 35037146 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-01-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36066139 in European review for medical and pharmacological sciences as Journal Article, with publication-date metadata of 2022-08 (month precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 23 for the reviewed Tirzepatide label family with a published date of 2025-07-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT03241706 at 2026-07-30T18:24:37.180Z. Its registry update date was 2025-07-25, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214457 with status AP dated 2025-07-22, and names glucagon among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215421 with status AP dated 2025-07-22, and names liraglutide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT07073014 at 2026-07-30T18:24:37.179Z. Its registry update date was 2025-07-18, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02430480 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was goserelin.
DailyMed lists Structured Product Labeling version 8 for the reviewed Teriparatide label family with a published date of 2025-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 40280279 in American journal of ophthalmology as Journal Article, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 6 for the reviewed Ziconotide label family with a published date of 2025-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.
PubMed lists PMID 23440834 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2013-01-31 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 26083192 in The Cochrane database of systematic reviews as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2015-06-17 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05706623 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-10, and PeptideScanner's reviewed identity mapping was apraglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219196 with status AP dated 2025-07-09, and names calcitonin salmon among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT07043361 at 2026-07-30T18:24:37.183Z. Its registry update date was 2025-07-09, and PeptideScanner's reviewed identity mapping was semaglutide.
PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06484868 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was metreleptin.
PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40577185 in Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova as Journal Article, Randomized Controlled Trial, English Abstract, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37888925 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.